SCHEMBL6392191

SCHEMBL6392191

Cn1c(=O)n(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cc(C#CCc3ccccc3)ccc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 5/20 0.75
SLC22A8 Q8TCC7 1/20 0.75
MAPT P10636 4/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PARG Q86W56 1/20 0.46
SRC P12931 1/20 0.43
PRKACA P17612 1/20 0.43
PRKACG P22612 1/20 0.43
PRKACB P22694 1/20 0.43
HIF1A Q16665 2/20 0.43
GRM4 Q14833 2/20 0.43
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.41
STAT6 P42226 1/20 0.41
CCR2 P41597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6393638 0.91 MMP13 (0.80) MMP13SLC22A8MAPTPARGGRM4
SCHEMBL6388683 0.89 MMP13 (0.74) MMP13SLC22A8MAPTTP53SMN1; SMN2
SCHEMBL6395655 0.88 MMP13 (0.81) MMP13SLC22A8PARGSRC
SCHEMBL6390652 0.88 MMP13 (0.78) MMP13SLC22A8MAPTSMN1; SMN2PARG
SCHEMBL6391740 0.88 MMP13 (0.78) MMP13SLC22A8MAPTPARGHIF1A
SCHEMBL6392298 0.86 MMP13 (0.69) MMP13SLC22A8MAPTTP53SMN1; SMN2
SCHEMBL6392558 0.86 MMP13 (0.72) MMP13SLC22A8PARGGRM4
SCHEMBL6244295 0.86 MMP13 (1.00) MMP13SLC22A8SMN1; SMN2PARGALDH1A1
SCHEMBL6390967 0.85 MMP13 (0.87) MMP13SLC22A8SMN1; SMN2PARGALDH1A1
SCHEMBL6394445 0.85 MMP13 (0.71) MMP13SLC22A8MAPTTP53PARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962922-B2 Alkynylated quinazoline compounds WARNER-LAMBERT COMPANY LLC (US) 2005-11-08 US claimed
US-20050245548-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD 2005-11-03 US claimed
EP-1465878-A1 ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS Warner-Lambert Company LLC (US) 2004-10-13 EP claimed
WO-2004007469-A1 NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 WO claimed
US-20030130278-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD (FR) 2003-07-10 US claimed
WO-2003033478-A1 ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-04-24 WO claimed
US-6962922-B2 Alkynylated quinazoline compounds WARNER-LAMBERT COMPANY LLC (US) 2005-11-08 US disclosed
US-20050245548-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD 2005-11-03 US disclosed
US-6911515-B2 Aqueous room temperature living radical polymerization of vinyl halides UNIVERSITY OF PENNSYLVANIA (US) 2005-06-28 US disclosed
US-6838535-B2 Process for the living radical polymerization of chlorine containing monomers UNIVERSITY OF PENNSYLVANIA (US) 2005-01-04 US disclosed
EP-1465878-A1 ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS Warner-Lambert Company LLC (US) 2004-10-13 EP disclosed
WO-2004007469-A1 NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 WO disclosed
US-20030130278-A1 Alkynylated fused ring pyrimidine compounds GAUDILLIERE BERNARD (FR) 2003-07-10 US disclosed
US-20030078353-A1 Aqueous room temperature living radical polymerization of vinyl halides UNIVERSITY OF PENNSYLVANIA 2003-04-24 US disclosed
WO-2003033478-A1 ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-04-24 WO disclosed
WO-2002077043-A1 PROCESS FOR THE LIVING RADICAL POLYMERIZATION OF CHLORINE CONTAINING MONOMERS UNIVERSITY OF PENNSYLVANIA (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130278-A1 Alkynylated fused ring pyrimidine compounds MMP13, TIMP3, MMP3 MMP13 1/4885SLC22A8 811/4885MAPT 4840/4885
US-20050245548-A1 Alkynylated fused ring pyrimidine compounds MMP13, TIMP3, MMP3 MMP13 1/4885SLC22A8 827/4885MAPT 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.